The FDA has already approved biosimilar versions of Herceptin from Celltrion, Samsung Bioepis and Mylan.
Herceptin is one of Roche’s top-selling drugs, bringing in about $6.93 billion in sales in 2018.
However, sales have been hit by increased biosimilar competition, according to the report.
More articles on pharmacy:
Bristol-Myers urges shareholders to support Celgene takeover
Novartis to pay $23M to settle claims it used charity payments as kickbacks
Martin Shkreli reportedly running his pharma company from prison
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
